Microrobots help deliver gene therapy for cystic fibrosis
Official title: Magnetic Microrobots Assist AAV4 for CFTR Gene Delivery Through Mucus Barrier
Funded at Michigan State University · NIH-11119342 · Data updated 2026-11-12
This study is exploring how tiny robots can help deliver a gene therapy directly to the lungs of people with cystic fibrosis, making it easier for the treatment to get through the thick mucus that usually blocks it, with the hope of improving lung function and reducing infections.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project start | May 10, 2025 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $235,500 |
| NIH project number | 1R21EB037346-01 |
| Project ID | NIH-11119342 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cystic fibrosis, particularly those experiencing severe lung complications due to mucus obstruction.
✕Less likely to help
Patients with cystic fibrosis who do not have significant mucus obstruction or those with advanced disease stages where gene therapy may not be effective may not benefit from this research.
What this research studies
This research investigates how magnetically controlled microrobots can assist in delivering a gene therapy for cystic fibrosis (CF) by overcoming mucus barriers in the lungs. The approach involves using adeno-associated virus (AAV4) to carry the CFTR gene, which is crucial for lung function, directly to the affected airway cells. By utilizing advanced imaging techniques, these microrobots are designed to navigate through the thick mucus that typically obstructs effective treatment delivery. The goal is to improve the efficiency of gene therapy for patients suffering from CF, potentially restoring their lung function and reducing infections.
Why it matters
Potential benefit: If successful, this research could significantly enhance the effectiveness of gene therapy for cystic fibrosis patients, leading to improved lung health and quality of life.
How similar studies have gone: While the use of microrobots in medical applications is a novel approach, preliminary studies in related fields have shown promise in using targeted delivery systems for gene therapy.
Where this research is happening
-
Michigan State University
East Lansing, United States Active
Researchers
- Principal investigator: Li, Jinxing — Michigan State University
- Study coordinator: Li, Jinxing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.